NCT01510873

Brief Summary

Symptoms of Primary Immune Thrombocytopenic Purpura (pITP), such as spontaneous bruising, menorrhagia, mucosal bleeding and other symptoms might significantly affect the HRQOL of pITP patients. However, very little evidence exists on HRQOL outcomes in patients diagnosed with pITP. The investigators project will aim at providing scientific community solid evidence based data on the extent to which HRQOL is compromised and in which specific area. The purpose of this study is thus to compare generic Health-related Quality of Life (HRQOL) profiles of adult patients with primary Immune Thrombocytopenic Purpura (pITP) with that of a matched Italian population control Group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
424

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2011

Typical duration for all trials

Geographic Reach
1 country

29 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2011

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

January 12, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

January 18, 2012

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2014

Completed
Last Updated

January 23, 2014

Status Verified

January 1, 2014

Enrollment Period

2.1 years

First QC Date

January 12, 2012

Last Update Submit

January 22, 2014

Conditions

Keywords

Health-related quality of lifeFatiguepITOPrimary Immune Thrombocytopenic Purpura

Outcome Measures

Primary Outcomes (1)

  • Comparison of HRQOL of patients with pITP with that of a matched Italian population control Group.

    By the end of the study.

Secondary Outcomes (4)

  • Patient-reported fatigue amongst the three different pITP groups

    By the end of the study.

  • Patient-reported fatigue amongst the three different pITP groups.

    By the end of the study.

  • Possible association between socio-demographic and clinical variables with patient reported health outcomes.

    By the end of the study.

  • To assess patients' preferences for involvement in treatment decision-making.

    By the end of the study.

Study Arms (3)

Newly Diagnosed pITP

Patients within 3 months from diagnosis.

Other: HRQOL evaluation

Persistent pITP

Patients between 3 to 12 months from diagnosis; includes patients not reaching spontaneous remission or not maintaining complete response off therapy.

Other: HRQOL evaluation

Chronic pITP

Patients with ITP lasting for more than 12 months.

Other: HRQOL evaluation

Interventions

Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research. The Questionnaire properly formatted will be distributed to all participating Centers prior to study start.

Chronic pITPNewly Diagnosed pITPPersistent pITP

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients (18 years of age or older) with confirmed diagnosis of pITP in any phase of the disease

You may qualify if:

  • A confirmed diagnosis of pITP in any phase of the disease;
  • Patients aged at least 18 years;
  • Informed consent provided

You may not qualify if:

  • Participating in other HRQOL investigations that might interfere with this study
  • Having any psychiatric condition or major cognitive impairment hampering self-reported HRQOL evaluation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (29)

Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza

San Giovanni Rotondo, Foggia, Italy

Location

Ospedale Generale Regionale "F. Miulli"

Acquaviva delle Fonti, Italy

Location

Azienda Ospedaliero-Universitaria Policlinico Consorziale

Bari, Italy

Location

Azienda Sanitaria Locale BA - Ospedale di Venere

Bari, Italy

Location

Ospedali Riuniti di Bergamo

Bergamo, Italy

Location

Ospedale Binaghi

Cagliari, Italy

Location

Ospedale Businco

Cagliari, Italy

Location

U.O.C. di Onco-Ematologia - Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche

Campobasso, Italy

Location

US Dipartimentale - Centro per le malattie del sangue - Ospedale Civile - S.Giacomo

Castelfranco Veneto, Italy

Location

Azienda Ospedaliero Universitaria

Foggia, Italy

Location

Azienda Ospedaliera Universitaria San Martino

Genova, Italy

Location

DIMI- Clinica Ematologica - Università degli studi di Genova

Genova, Italy

Location

Ospedale Santa Maria Goretti

Latina, Italy

Location

Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte"

Messina, Italy

Location

Azienda Ospedaliera Universitaria - Policlinico "G. Martino"

Messina, Italy

Location

Azienda Ospedaliero - Universitaria di Modena

Modena, Italy

Location

Azienda Ospedaliera "S. Gerardo dei Tintori"

Monza, Italy

Location

S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro

Novara, Italy

Location

Ospedale S. Luigi Gonzaga

Orbassano, Italy

Location

Azienda Ospedaliera Universitaria - Policlinico Paolo Giaccone

Palermo, Italy

Location

Azienda Ospedaliero - Universitaria di Parma

Parma, Italy

Location

Azienda Ospedaliera "Bianchi - Melacrino - Morelli"

Reggio Calabria, Italy

Location

U.O.C. Ematologia - Ospedale S.Eugenio

Roma, Italy

Location

U.O.S.A. Ematologia ASL RMA Presidio Nuovo Regina Margherita

Roma, Italy

Location

UOC Pronto Soccorso e Accettazione Ematologica - Dipartimento Biotecnologie Cellulari ed Ematologia - Università degli Studi di Roma "Sapienza"

Rome, Italy

Location

U.O. Ematologia, Azienda Ospedaliera Universitaria Senese

Siena, Italy

Location

Azienda Ospedaliero - Universitaria "San Giovanni Battista"

Torino, Italy

Location

Azienda Ospedaliera

Treviglio, Italy

Location

ULSS N.6 Ospedale San Bortolo

Vicenza, Italy

Location

Related Links

MeSH Terms

Conditions

Purpura, Thrombocytopenic, IdiopathicFatigue

Condition Hierarchy (Ancestors)

Purpura, ThrombocytopenicPurpuraBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesThrombotic MicroangiopathiesThrombocytopeniaBlood Platelet DisordersCytopeniaHemorrhagic DisordersAutoimmune DiseasesImmune System DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsSkin ManifestationsSigns and Symptoms

Study Officials

  • Fabio Efficace, PhD

    GIMEMA DATA CENTER, ROME, ITALY

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 12, 2012

First Posted

January 18, 2012

Study Start

December 1, 2011

Primary Completion

January 1, 2014

Study Completion

January 1, 2014

Last Updated

January 23, 2014

Record last verified: 2014-01

Locations